The need for -60°C through -80°C assets to help future-proof manufacturing facilities has increased significantly over the past decade - clinical research investments have expanded while commercial-scale needs continue to transform the landscape. Cold wall remains the gold standard due to a lack of alternative solutions. Several factors, however, have placed stress on cold-wall technologies to perform in applications for which they were not designed or intended.

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Safeguarding Performance and Sample Integrity: Solutions to Achieve Flexibility in Freezing and Storage Applications

Newsletter